ORI Capital
Finance · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Sun Hung Kai Centre Wanchai 30 Harbour R...Phone Number
+86 85238981500Website
www.ori-capital.comRevenue
<$5 MillionIndustry
About ORI Capital
ORI Capital Org Chart
Senior Partner
Investment Analyst
Research Analyst
Research Analyst
Investment & Research Summer Analyst
Research Analyst
Research Analyst
Investment Analyst
Is ORI Capital your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if ORI Capital has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on ORI Capital recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when ORI Capital launches new products
Check out if ORI Capital is spiking on competitors!
Funding: Get notified immidiatlly once ORI Capital has new funding data
Congratulate Masked Content for being promoted to Masked Content at ORI Capital
ORI Capital, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if ORI Capital had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at ORI Capital
Find 3 more new buyers
Company Profile Activity
Activity Insights
ORI Capital is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
ORI Capital is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about ORI Capital.
ORI Capital financials insights
Gather financial insights about ORI Capital, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Other Financing Round
$18M
ORI Capital Tech Stack
A closer look at the technologies used by ORI Capital
ORI Capital News & Media
CG Oncology Raises $120M in Series E Financing
CG Oncology, an Irvine, CA-based oncolytic immunotherapy company, raised $120M in Series E funding. The round was co-led by ORI Capital, Longitude Capital and Decheng Capital, with participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group and Sirona Capital. In connection with the financing, Brian Liu, M.D., Principal from Longitude Capital, will join […] The post CG Oncology Raises $120M in Series E Financing appeared first on FinSMEs.AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
NATICK, Mass., Oct. 7, 2021 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company developing and deploying its Tune & Track platform for the use of CAR T cells to treat solid tumors, announced today the close of a $30 million Series A+ funding by ORI...ORI Capital's Portfolio Company Pillar Receives FDA Premarket Approval for its oncoReveal(TM) Dx Lung and Colon Cancer Test
Pillar's Mission - to Make Precision Medicine the First Line Treatment for all Cancer Patients HONG KONG, Aug. 6, 2021 /PRNewswire/ -- ORI Capital, a quantamental healthcare fund manager focused on investing in disruptive healthcare companies globally, announced today the U.S. Food and Drug Administration (FDA) has given its portfolio company, Pillar Biosciences Inc. ("Pillar"), Premarket Approval (PMA) for Pillar's oncoReveal™ Dx Lung and Colon Cancer Test (ORDx-LCCA). The test is an NGS tissue
Top Finance Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ORI Capital
ORI Healthcare Fund L.P. is a privately owned venture capital company. It provides priced capital for the healthcare and technology industry. The company was established in 2015 and is based in Wanchai, Hong Kong.... Read More